Paul Conyngham, the Australian tech entrepreneur who publicized a story about using AI tools to help design a cancer vaccine for his dog, has launched a startup around the idea, according to The Verge. The company, Gamgee, says it will offer “personalised mRNA cancer vaccines for dogs.” The pitch is broader than veterinary oncology. The Verge reports that Gamgee’s website describes a plan to use AI and genetics to develop personalized treatments across diseases and species, including humans. The company’s public-facing story is built around Rosie, Conyngham’s Staffordshire bull terrier–Shar Pei mix, who appears in the startup’s materials and in Conyngham’s social posts. Conyngham said on X that he used ChatGPT and computational genomics to design a personalized mRNA cancer vaccine for Rosie’s tumor, and that several of her tumors shrank, The Verge reports. Gamgee’s site also stresses that Conyngham is “not a biologist,” while framing the company’s mission as scaling what he says helped extend Rosie’s life. The evidentiary picture is much less settled than the startup narrative. The Verge says its earlier reporting found that the exact role AI played in Rosie’s treatment was unclear. Researchers told the outlet that broad claims around the case appeared to give AI too much credit while underplaying the human expertise involved. The Verge also reports that Rosie received the mRNA vaccine alongside another therapy, which means the improvement cannot be clearly attributed to the vaccine from the described protocol. That uncertainty has not stopped the company from attracting institutional startup backing. The Verge reports that Gamgee is backed by Y Combinator and says it is recruiting for its first clinical trials in Australia. The company has opened a waitlist elsewhere, while Conyngham says it is “accepting cases globally,” according to the outlet. Gamgee is also making operational claims to veterinarians. The Verge reports that a veterinarian-focused section of the company’s website cites roughly 75% tumor reduction in its “first documented case,” says the process would require less than 20 minutes of a veterinarian’s time, and targets a finished vaccine in about four weeks. The company cautions that the timeline is based on a single case and may vary. The site does not disclose costs, according to The Verge. The company says it is working with the University of Queensland and institutes at the University of New South Wales in Australia, The Verge reports. Conyngham is also soliciting potential funders and study partners. For now, Gamgee is best understood as a high-visibility AI-biotech startup formed around a compelling but scientifically unresolved anecdote. The company’s first serious test will be whether clinical work can separate a reproducible therapeutic effect from a single case in which AI’s role and the vaccine’s contribution remain unclear. Who benefits: Gamgee benefits from a memorable origin story, Y Combinator backing and public interest in AI-assisted medicine. Pet owners seeking experimental cancer options may also follow the company’s trials or waitlist, subject to what the clinical process establishes. Who's exposed: Gamgee is exposed to scientific and credibility risk if trials do not support claims implied by Rosie’s case. Veterinarians and prospective partners also face uncertainty because the reported timeline and tumor-reduction claim are tied to a single documented case.